Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of abiraterone combined with prednisone on serum CgA and NSE in metastatic castration-resistant prostate cancer without previous chemotherapy

Ke Yang¹, Tieqiu Li¹, Zhiyong Gao¹, Weiwei Zhang²

¹Department of Urology, Hunan Provincial People's Hospital, Changsha City 410005, Hunan; ²Department of Urology, Jinhua Central Hospital, Jin Hua city, 321000, Zhejiang Province, China.

For correspondence:- Weiwei Zhang Email: ej1305@163.com

Accepted: 25 February 2019 Published: 31 March 2019

Citation: Yang K, Li T, Gao Z, Zhang W. Effect of abiraterone combined with prednisone on serum CgA and NSE in metastatic castration-resistant prostate cancer without previous chemotherapy. Trop J Pharm Res 2019; 18(3):631-637 doi: 10.4314/tjpr.v18i3.27

© 2019 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the influence of a combination of abiraterone and prednisone on serum chromogranin A (CgA) and neuron-specific enolase (NSE) in patients with metastatic castration-resistant prostate cancer (mCRPC) without previous chemotherapy, so as to provide reference data for drug therapy of prostate cancer.

Methods: A total of 103 mCRPC patients without chemotherapy from January 2013 to March 2017 were included in this retrospective study. Seventy-one (71) patients received prednisone combined with abiraterone (study group), while 32 patients accepted prednisone (control group). The CgA, NSE and prostate-specific antigen (PSA) in the two groups were monitored, while PSA progression-free survival (PSA-PFS), radiographic PFS (rPFS), and overall survival (OS) were determined during follow-up.

Results: PSA-PFS, rPFS and OS in the study group were significantly higher than those in the control group (p < 0.05). The increased proportion of CgA or NSE in the study group was significantly lower than that in the control group at 6 months of treatment (p < 0.05). The occurrences of NED before treatment and 6 months after treatment were both independent predictors of PSA and radiographic progression in the study group (p < 0.05).

Conclusion: The combination of prednisone and abiraterone is helpful for prognosis in mCRPC patients that are not on chemotherapy. The occurrence of NED predicts mostly poor prognosis of mCRPC patients on a combination of abiraterone and prednisone.

Keywords: Abiraterone, Metastatic castration-resistant prostate cancer, Neuroendocrine, Chromogranin A, Neuron-specific enolase